C. Anti Cancer Drugs

DNA or RNA Synthesis Inhibitors

Description Note
Actinomycin D, 97.0+% (HPLC), Wako1st Grade
Wako Cat. #018-21264 (1 mg); 014-21261 (5 mg); 010-21263 (25 mg)
Antibiotic. Selectively inhibit RNA synthesis (specially rRNA synthesis) by binding to the DNA.
Bleomycin Hydrochloride<for Cellbiology>
Wako Cat. #028-07801 (10 mg) Potency: 1,400~2,000 μg/mg
Antibiotics. Exhibit an antitumor activity by inhibiting DNA synthesis and cleaving DNA strands.
Bleomycin Sulfate<for Pharmacology Research>
Wako Cat. #027-15941 (10 mg); 023-15943 (50 mg)
1,4-Butanediol Dimethanesulfonate [Busulfan], 97.0+% (cGC) <Wako1st Grade>
Wako Cat. #029-09352 (25 g)
Alkylating compound: Inhibit synthesis and duplication of DNA by alkylation of nucleic acids (mainly DNA) and other cell components to suppress cell division.
Carboplatin, 97.0+% (HPLC) <for Cellbiology>
Wako Cat. #039-16041 (25 mg); 035-16043 (250 mg)
Platinum complex: Form crosslinks in double stranded DNA. Inhibit DNA synthesis followed by cell division.
Cisplatin, 98.0+% (HPLC) <for Pharmacology Research>
Wako Cat. #033-20091 (200 mg); 039-20093 (2 g)
Cyclophosphamide Monohydrate, 97.0+% (Titration) <for Cellbiology>
Wako Cat. #030-12953 (1 g); 034-12951 (5 g)
Alkylating compound: Inhibit synthesis and duplication of DNA by alkylation of nucleic acids (mainly DNA) and other cell components to suppress cell division.
Dacarbazine, 98.0+% (Potentiometric titration) <for Pharmacology Research>
Wako Cat. #047-29951 (200 mg); 043-29953 (1 g)
Alkylating compound: Cause DNA-damage by alkylation with diazomethane produced by metabolism.
Daunorubicin Hydrochloride<for Pharmacology Research>
Wako Cat. #043-30041 (5 mg); 049-30043 (50 mg)
Anthracycline antibiotic. Inhibit DNA synthesis by binding the DNA. Induce apoptosis by Fas in Jurkat cells.
Ifosfamide, 98.0+% (HPLC) <for Pharmacology Research>
Wako Cat. #090-05401 (50 mg); 096-05403 (500 mg)
Alkylating compound: Its active metabolites, 4-hydroxy ifosfamide and aldoifosfamide inhibit DNA synthesis of tumor cells.
Melphalan<for Pharmacology Research>
Wako Cat. #135-15251 (100 mg); 131-15253 (1 g)
Alkylating compound: Considered to exhibit an antitumor eff ect by inhibiting nucleic acid synthesis caused by crosslinking formation between intra- or inter-DNA strands and between DNA and proteins.
Mitomycin C <for Cellbiology>
Wako Cat. #134-07911 (10mg) Potency: 850+μg/mg
Antibiotic that causes crosslink breakage by binding to guanine residues of DNA and induces inhibition of DNA biosynthesis.
Nimustine Hydrochloride, 97.0+% (Titration) <for Pharmacology Research>
Wako Cat. #142-08471 (250 mg); 148-08473 (1 g)
Alkylating compound: Water-soluble nitrosourea derivative. The main action mechanism is considered to be depolymerization of DNA and inhibition of DNA synthesis by DNA alkylation.
Oxaliplatin, 97.0+% (HPLC) <for Pharmacology Research>
Wako Cat. #156-02691 (5 mg); 152-02693 (50 mg)
Platinum complex, form crosslinks in double stranded DNA. Inhibit DNA synthesis followed by cell division.
Procarbazine Hydrochloride, 98.0+% (Titration) <for Pharmacology Research>
Wako Cat. #161-22581 (100 mg); 167-22583 (1 g)
Alkylating compound: Inhibit nucleic acid/protein synthesis by alkylating nucleic acids.
page top

Topoisomerase and Telomerase Inhibitors

Description Note
17-AAG<for Cellbiology>
Wako Cat. #012-20101 (1 mg)
Cause dephosphorylation of Akt by inhibition of HSP90 followed by inactivation of Akt and apoptosis.
Camptothecin, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #038-18191 (100 mg); 034-18193 (500 mg)
Reversible Topoisomerase I inhibitor: Cause DNA-damage by binding to and stabilizing topoisomerase-DNA complex.
Doxorubicin Hydrochloride [Adriamycin Hydrochloride]
<for Biochemistry>
Wako Cat. #040-21521 (10 mg); 046-21523 (50 mg) Potency: 900+ μg/mg
Anthracycline antibiotic: Cause DNA-damage by inhibiting Topoisomerase II.
Ellagic Acid Dihydrate, 99.0+% (HPLC) <for Biochemistry>
Wako Cat. #056-05781 (5 g); 054-05782 (25 g)
Potent antioxidant that has antimutagenic and anticarcinogenic eff ects. Inhibits Topoisomerase I and II.
(-)-Epigallocatechin Gallate, 90.0+% (HPLC) <for Biochemistry>
Wako Cat #059-05411 (100 mg)
Considered to act on a unit having reverse transcriptase activity, hTERT. Polyphenol: Catechin from green tea extracts
Epirubicin Hydrochloride<for Pharmacology Research>
Wako Cat. #058-07561 (1 mg); 054-07563 (5 mg)
An anthracycline antibiotic: Stereoisomer of doxorubicin with an inverse stereochemistry of the OH group in the 4’ position. Show less toxicity than doxorubicin hydrochloride.
Etoposide Phosphate, 85.0+% (HPLC) <for Biochemistry>
Wako Cat. #058-06341 (5 mg)
Water-soluble derivative of etoposide. Cause DNA-damage by inhibiting Topoisomerase II.
Geldanamycin, from Streptomyces hygroscopicus, 95.0+% (HPLC) <for Biochemistry>
Wako Cat. #077-04571 (100 μg)
Inhibit chaperone activity of HSP90.
Nalidixic Acid, 98.5+% (Titration) <for Biochemistry>
Wako Cat. #148-04791 (5 g); 146-04792 (25 g)
Causes DNA-damage by inhibiting DNA gyrase.
page top

Cytoskeletal Inhibitors and Cell-Division Inhibitors

Description Note
Colchicine, 95.0+% (HPLC) < Wako1st Grade>
Wako Cat. #039-03851 (100 mg); 035-03853 (1 g)
Microtubule depolymerizing agent. Cell cycle synchronizing agent. Act as an ending factor of tubulin polymerization by binding to tubulin dimer, which induces inhibition of tubulin polymerization with very small concentration.
Cytochalasin B, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #030-17551 (1 mg); 036-17553 (5 mg); 034-17554 (10 mg)
Bind to F-actin and induce depolymerization of F-actin by capping function that inhibits assembly of G-actin. Inhibit cytokinesis but not karyokinesis.
Cytochalasin D, 95.0+% (TLC) <for Biochemistry>
Wako Cat. #037-17561 (1 mg); 033-17563 (10 mg)
Have nearly the same function as that of cytochalasin B, but do not show inhibitory activity in glucose transport unless stimulated by insulin.
Demecolcine, 90.0+% (Absorptiometry) <for Biochemistry>
Wako Cat. #045-16963 (5 mg); 049-16961 (20 mg)
Microtubule depolymerizing agent. Cell cycle synchronizing agent. Have nearly the same function as and less toxicity than that of colchicine.
Latrunculin A, 93.0+% (HPLC) <for Biochemistry>
Wako Cat. #125-04363 (1 mg); 129-04361 (5 mg)
Inhibit actin polymerization by binding with G-actin.
Latrunculin B <for Cellbiology>
Wako Cat. #129-05101 (1 mg)
Mycalolide B, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #132-12081 (100 μg)
Paclitaxel, 97.0+% (HPLC) <for Biochemistry>
Wako Cat. # 169-18616 (1 mg); 169-18611 (5 mg); 165-18613 (25mg);163-18614 (100 mg)
Plant alkaloid: Bind to β-tubulin and stabilize microtubule, inducing inhibition of mitosis by inhibiting microtubule dynamics.
Phalloidin, 95.0+% (TLC) <for Biochemistry>
Wako Cat. #165-15411 (1 mg)
Inhibit actin depolymerization by binding to and stabilizing F-actin.
Podophyllotoxin, 95.0+% (HPLC) <for Biochemistry>
Wako Cat. #161-20901 (100 mg); 167-20903 (1 g)
Antimitotic agent. Bind in the vicinity of colchicine binding site of tubulin dimer and competitively inhibit microtubule formation by colchicine.
Swinholide A <for Biochemistry>
Wako Cat. #197-11851 (10 μg )
Cleave actin fi laments by binding to G-actin and stabilizing actin dimer.
Vinblastine Sulfate, 97.0+% (HPLC) <for Biochemistry>
Wako Cat. #221-00751 (10 mg); 227-00753 (50 mg)
Plant alkaloid: Inhibit polymerization by exerting a selective action on tubulin, a structural protein of microtubule, during mitosis. Inhibit tubulin polymerization with low concentration and induce polymorphic assembly of tubulin with high concentration.
Vindesine Sulfate, 96.0+% (HPLC) <for Pharmacology Research>
Wako Cat. #225-01631 (2 mg); 221-01633 (10 mg)
Plant alkaloid: Considered to exhibit an antitumor eff ect by acting on microtubule or tubulin, a structural protein of microtubule, during mitosis.
Vinorelbine Ditartrate, 98.0+% (HPLC) <for Pharjmacology Research>
Wako Cat. #222-01641 (10 mg); 228-01643 (50 mg)
Plant alkaloid: Inhibit polymerization by exerting a selective action on tubulin, a structural protein of microtubule, during mitosis.
page top

Antiangiogenic agents

Description Note
Angiostatin, from Human <for Biochemistry>
Wako Cat. #543-00941 (1 mg)
Considered to regulate induction of excessive vascularization by inhibiting migration of vascular endothelial cells.
Fumagillin, 95+% (TLC) <for Biochemistry>
Wako Cat. #065-04071 (1 mg); 061-04073 (5 mg)
Antibiotic: Inhibit biosynthesis of sphingomyelin. Have a vascularization inhibitory activity.
Irsogladine Maleate, 97.0+% (Titration) <for Biochemistry>
Wako Cat. #098-04581 (100 mg); 094-04583 (500 mg)
Antiulcer drug. Inhibit vascularization in HOMEC and mouse CP assay.
2-Methoxyestradiol <for Cellbiology>
Wako Cat. #138-15501 (10 mg); 134-15503 (50 mg)
Low molecular antiangiogenic agent without estrogenic activity. Inhibit microtubule assembly by binding to colchicine binding site of tubulin and arrest cell division in metaphase.
Radicicol <for Cellbiology>
Wako Cat. #183-01901 (1 mg)
Antibacterial macrocyclic lactone antibiotic with antimalarial activity.Have the ability to inhibit HSP90 and protein tyrosine kinase and show vascularization inhibitory activity.
Suramin Sodium, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #199-10613 (100 mg); 193-10611 (200 mg)
Considered to have a vascularization inhibitory eff ect by preventing various growth factors from binding to the cell surface. Inhibit interaction between G protein and intracellular receptor site.
(±)-Thalidomide, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #200-15131 (100 mg); 206-15133 (1 g); 204-15134 (10 g)
Inhibit biosynthesis of TNFA. Inhibit vascularization by bFGF in rabbit CP assay.
page top

Antimetabolite

Description Note
Carmofur <for Pharmacology Research>
Wako Cat. #035-20051 (1 g); 031-20053 (5 g)
Pyrimidine antimetabolite. Prodrug of 5-FU. Metabolized in vivo into 5-FU and inhibit DNA synthesis.
Chlormadinone Acetate, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #035-15161 (1 g); 031-15163 (5 g)
Synthetic hormone agent: One of corpus luteum hormones. Inhibit eff ect of hormone relating to the prostate hyperplasia.
Cytosine-1B-D(+)-arabinofuranoside [Cytarabine], 98.0+% (HPLC)
<for Biochemistry>
Wako Cat. #030-11951 (100 mg); 034-11954 (500 mg); 036-11953 (1 g)
Antimetabolic drug: Antipyrimidine. Cytarabine triphosphate phosphorylated in cells strongly inhibits DNA polymerase I. In particular,strongly inhibit DNA synthesis.
page top

Antimetabolite

Description Note
Dexamethasone, 98.0~102.0% (Titration) <for Biochemistry>
Wako Cat. #047-18863 (100 mg); 041-18861 (1 g)
Synthetic hormone agent: Synthetic adrenal cortical hormone.Glucocorticoid. Inhibit phospholipase.
Doxifl uridine <for Pharmacology Research>
Wako Cat. #042-29901 (100 mg); 048-29903 (1 g)
Pyrimidine antimetabolite. Prodrug of 5-FU. Metabolized in vivo into 5-FU and inhibit DNA synthesis.
5-Fluorouracil [5-FU], 98.5+% (HPLC) <Wako Special Grade>
Wako Cat. #068-01401 (1 g); 064-01403 (5 g); 066-01402 (25 g)
Antipyrimidine. The metabolite inhibits DNA synthesis by inhibiting thymidylate synthase. It is incorporated into RNA instead of uracil and kills the cells.
Flutamide, 98.0+% (HPLC) <for Pharmacology Research>
Wako Cat. #069-04851 (2 g); 065-04853 (10 g)
Synthetic hormone agent: Nonsteroidal antiandrogen. Inhibit androgen binding to androgen receptor.
Hydroxyurea [Hydroxycarbamide], 90.0+% (Titration)
<Practical Grade >
Wako Cat. #085-06653 (5 g); 089-06651 (10 g)
Antimetabolic drug: Inhibit nucleoside diphosphate reductase in the DNA synthesis specifi c metabolic process and terminate DNA replication.
Medroxyprogesterone Acetate, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #138-09991 (1 g); 134-09993 (5 g)
Synthetic hormone agent: Corpus luteum hormone agonist with antitumor activity. Inhibit vascularization.
6-Mercaptopurine Monohydrate, 98.0~102.0%
<for Biochemistry>
Wako Cat. #130-07991 (1 g); 136-07993 (5 g)
Antipurine. Inhibit nucleic acid (DNA) synthesis by binding to inosinic acid (IMP).
Methotrexate, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #139-13571 (100 mg); 135-13573 (1 g)
Antifolic. Inhibit enzyme activity and purine synthesis by tightly binding to the active folate producing enzyme.
Prednisolone, 97.0~103.0% (Absorptiometry) <for Biochemistry>
Wako Cat. #165-11491 (1 g); 161-11493 (5 g)
Synthetic hormone agent: Synthetic steroid hormone. Have action of adrenal cortical hormone and inhibit phospholipase.
Tamoxifen Citrate, 98.0+% (Titration) <for Biochemistry>
Wako Cat. # 209-14361 (250 mg); 205-14363 (1 g); 203-14364 (5 g);207-14362 (25 g)
Synthetic hormone agent: Estrogen analog. Selectively bind to estrogen receptor. Exhibit estrogenic eff ect in the tissues such as bone and heart, and inhibit action of estrogen in the breasts and uterus.
1-(2-Tetrahydrofuryl)-5-fl uorouracil [Tegafur] 98.0+% (Titration)
<for Biochemistry>
Wako Cat. #206-10351 (1 g); 202-10353 (5 g)
Antipyrimidine. Prodrug of 5-FU. Metabolized in vivo into 5-FU and inhibit DNA synthesis.
Toremifene Citrate (mixture of isomers), 98.0+% (Titration)
<for Pharmacology Research>
Wako Cat. #200-16971 (500 mg); 206-16973 (2 g)
Inhibit binding of estradiol to the estrogen receptor. Considered to have cell-growth inhibitory activity by estradiol and by blocking of signaling pathway via IGF-1 receptor.
page top

Others

Description Note
AACOCF3 [Arachidonyltrifl uoromethylketone] <for Biochemistry>
Wako Cat. #011-18461 (10mg)
Selective inhibitor of cPLA2 (Cytosolic phospholipase A2) and iPLA2 (Ca2+ independent phospholipase A2) (IC50=15 μmol/L).
AITRL, Human, recombinant <for Cellbiology>
Wako Cat. #014-19671 (20 μg)
One of the costimulatory molecules of TNF/TNF receptor family. AITRLAITR interaction is important to control apoptosis via T cell proliferation or TCR.
all-trans-Retinoic Acid [Tretinoin], 97.0+% (HPLC) <for Biochemistry>
Wako Cat. # 186-01114 ( 50 mg); 182-01116 (100 mg);182-01111 (250 mg); 188-01113 ( 1 g)
Synthetic retinoids: Retinoic acids are considered to regulate proliferation and diff erentiation of cells by directly controlling gene expression in vivo.
Am580, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #014-16631 (5 mg)
Am80, 98.0+% (HPLC) <for Biochemisty>
Wako Cat. #017-16621 (5 mg)
Ch 55, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #039-16781 (5 mg)
4-Amino-1,8-naphthalimide <for Biochemistry>
Wako Cat. #018-18611 (20 mg)
Strongly inhibit PARP. (IC50=0.18 μmol/L)
Anisomycin, 96.0+% (HPLC) <for Biochemistry>
Wako Cat. #017-16861 (10 mg); 013-16863 (50 mg); 011-16864 (250 mg)
Activator of p54 and MAP kinase. Involved in activation of SAPKs. Induce apoptosis in human U937 cells.
(+)-Brefeldin A <for Cellbiology>
Wako Cat. #022-15991 (5 mg); 028-15993 (25 mg)
Macrolide Antibiotic: Specifically and reversibly inhibit protein transport from endoplasmic reticulum to Golgi apparatus without aff ecting endocytosis or lysosome function.
Calpain Inhibitor I <for Cellbiology>
Wako Cat. #031-19801 (10 mg )
Inhibit neutral cysteine proteases, such as calpain 1, calpain 2, cathepsin B and cathepsin L, and proteasome. Inhibit apoptosis in thymocytes and metamyelocytes.
Caspase 6/caspase 8 inhibitor W-1 [Ac-IETD-CHO], 92.0+% (HPLC)
<for Biochemistry>
Wako Cat. #034-17331 (1 mg)
Specifically and reversibly inhibit Caspase 6 / Caspase 8 and related cysteine protease.
Caspase3/CPP32 Inhibitor W-3 [Z-DEVD-FMK], 95.0+% (TLC)
<for Biochemistry>
Wako Cat. #034-16971 (1 mg)
Specifically inhibit cysteine protease activity of caspase 3. Have membrane permeability
page top

Others

Description Note
CPP32/Apopain Inhibitor W-1 [AC-DEVD-CHO], 95.0+% (HPLC)
<for Biochemistry>
Wako Cat. #037-16961 (5 mg)
Caspase-3 inhibitor
Cytotrienin A <for Biochemistry>
Wako Cat. #039-18241 (100 μg)
Antibiotic derived from actinomycetes. Low concentration treatment (10ng/mL) induces apoptosis in HL-60.
Deguelin <for Cellbiology>
Wako Cat. #047-29211 (5 mg)
Akt inhibitor. Inhibit cell proliferation in G2-M period . Induce apoptosis in precancerous and cancerous cell lines.
Granzyme B Inhibitor W-2 [Z-AAD-CMK], 90.0+% (HPLC)
<for Biochemistry>
Wako Cat. #076-04301 (1 mg)
Inhibit human and mouse serine proteases, granzyme B.
Herbimycin A, 98.0+% (HPLC) <for Biochemistry>
Wako Cat. #085-06491 (1 mg)
Inhibit tyrosine kinase of src by reacting with SH groups of cis residues in src.
Leupeptin Hemisulfate Monohydrate <for Biochemistry>
Wako Cat. # 122-03751 (5 mg); 126-03754 (10 mg); 128-03753 (25 mg);122-03756 (100 mg)
Cysteine protease inhibitor: Show inhibitory eff ect of papain and cathepsin B.
Pamidronate Disodium Salt Pentahydrate, 98.0+% (HPLC)<for Pharmacology Research>
Wako Cat. #165-23101 (10 mg); 161-23103 (100 mg)
Bone resorption inhibitor: Lower serum calcium level in patients with hypercalcemia caused by cancer.
Staurosporine, 95.0+% (HPLC) <for Biochemistry>
Wako Cat. #197-10251 (100 &mu;g); 193-10253 (500 &mu;g)
Potent PKC inhibitor (IC50=2.7 nmol/L): Also inhibit PKA (IC50=8.2 nmol/L) and p60v-src tyrosine kinase, the product of src, (IC50=6.4 nmol/L) to a similar extent.
Tunicamycin, 95.0+% (HPLC) <for Biochemistry>
Wako Cat. #202-08241 (10 mg); 208-08243 (50 mg)
Inhibit N-linked glycosylation of glycoproteins by inhibiting the first reaction of glycoprotein synthesis system via the lipid intermediate pathway. Induce apoptosis mediated by endoplasmic reticulum stress.
(+)-Wortmannin [KY12420] <for Cellbiology>
Wako Cat. #230-02341 (2 mg); 236-02343 (10 mg)
Have cell permeability and irreversibly inhibit PI3 kinase. Inhibit myosin light chain kinase at high concentration.
Y-27632, 98.0+% (HPLC) <for Cellbiology>
Wako Cat. #257-00511 (1 mg); 253-00513 (5 mg)
Selective and potent ROCK inhibitor. Specifically suppress morphological changes in apoptosis.
page top

Immunostimulant

Description Note
Bestatin, abt. 98.0+% (HPLC)
Wako Cat. #027-14101 (100 mg)
Protease inhibitor: Specifically inhibit aminopeptidase B, leucine aminopeptidase, tripeptide aminopeptidase, and aminopeptidase on the membrane of mammalian cells.
page top
backindex
Wako Product Update Bio-No.3 [ page. 9 ]